A French biotechnology company, Da Volterra, is currently conducting a survey to evaluate the consequences of Clostridium difficile infections (CDI) on the quality of life of patients during the acute infection. This study will also explore the post-CDI symptoms that patients might experience.
If you face or have faced a C. diff infection, please take this short survey to help healthcare professionals learn more about CDI patients’ quality of life: https://cdiffsurvey.org
This study will help physicians, healthcare providers, and policy makers understand the burden of CDI and to strengthen the need for therapies to combat and prevent CDI.
Da Volterra expects to publish the results and disseminate them widely to let people know the true burden of CDI for patients. They currently have no formal end date; they hope to have at least 342 respondents and plan to keep the survey online until then.